Vitamin D Receptor Antibody - #AF6159

(7)   (10)  
Product: Vitamin D Receptor Antibody
Catalog: AF6159
Description: Rabbit polyclonal antibody to Vitamin D Receptor
Application: WB IHC IF/ICC
Reactivity: Human, Mouse
Prediction: Pig, Horse, Chicken
Mol.Wt.: 48kDa; 48kD(Calculated).
Uniprot: P11473
RRID: AB_2835028

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse
Prediction:
Pig(86%), Horse(86%), Chicken(100%)
Clonality:
Polyclonal
Specificity:
Vitamin D Receptor Antibody detects endogenous levels of total Vitamin D Receptor.
RRID:
AB_2835028
Cite Format: Affinity Biosciences Cat# AF6159, RRID:AB_2835028.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

1 25 dihydroxyvitamin D3 receptor; 1; 1,25 dihydroxyvitamin D3 receptor; 1,25-@dihydroxyvitamin D3 receptor; 25-dihydroxyvitamin D3 receptor; Member 1; NR1I1; Nuclear receptor subfamily 1 group I member 1; PPP1R163; Protein phosphatase 1, regulatory subunit 163; VDR; VDR_HUMAN; Vitamin D (1,25- dihydroxyvitamin D3) receptor; Vitamin D hormone receptor; Vitamin D nuclear receptor variant 1; Vitamin D receptor; Vitamin D3 receptor;

Immunogens

Immunogen:
Uniprot:

P11473(VDR_HUMAN) >>Visit HPA database.

Gene(ID):
VDR(7421)
Description:
Nuclear hormone receptor. VDR mediates the action of vitamin D3 by controlling the expression of hormone sensitive genes.
Sequence:
MEAMAASTSLPDPGDFDRNVPRICGVCGDRATGFHFNAMTCEGCKGFFRRSMKRKALFTCPFNGDCRITKDNRRHCQACRLKRCVDIGMMKEFILTDEEVQRKREMILKRKEEEALKDSLRPKLSEEQQRIIAILLDAHHKTYDPTYSDFCQFRPPVRVNDGGGSHPSRPNSRHTPSFSGDSSSSCSDHCITSSDMMDSSSFSNLDLSEEDSDDPSVTLELSQLSMLPHLADLVSYSIQKVIGFAKMIPGFRDLTSEDQIVLLKSSAIEVIMLRSNESFTMDDMSWTCGNQDYKYRVSDVTKAGHSLELIEPLIKFQVGLKKLNLHEEEHVLLMAICIVSPDRPGVQDAALIEAIQDRLSNTLQTYIRCRHPPPGSHLLYAKMIQKLADLRSLNEEHSKQYRCLSFQPECSMKLTPLVLEVFGNEIS

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Chicken
100
Pig
86
Horse
86
Bovine
0
Sheep
0
Dog
0
Xenopus
0
Zebrafish
0
Rabbit
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P11473 As Substrate

Site PTM Type Enzyme
S51 Phosphorylation P17252 (PRKCA) , P05771 (PRKCB)
K117 Ubiquitination
S119 Phosphorylation
K123 Ubiquitination
S125 Phosphorylation
S172 Phosphorylation
T175 Phosphorylation
S182 Phosphorylation P17612 (PRKACA)
S208 Phosphorylation P68400 (CSNK2A1)
Y293 Phosphorylation
K302 Ubiquitination
Y380 Phosphorylation
K386 Ubiquitination
S392 Phosphorylation
K399 Ubiquitination

Research Backgrounds

Function:

Nuclear receptor for calcitriol, the active form of vitamin D3 which mediates the action of this vitamin on cells. Enters the nucleus upon vitamin D3 binding where it forms heterodimers with the retinoid X receptor/RXR. The VDR-RXR heterodimers bind to specific response elements on DNA and activate the transcription of vitamin D3-responsive target genes. Plays a central role in calcium homeostasis (By similarity).

Subcellular Location:

Nucleus. Cytoplasm.
Note: Localizes mainly to the nucleus (PubMed:28698609, PubMed:12145331). Localization to the nucleus is enhanced by vitamin D3.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Subunit Structure:

Homodimer in the absence of bound vitamin D3. Heterodimer with RXRA after vitamin D3 binding. Interacts with MED1, NCOA1, NCOA2, NCOA3 and NCOA6 coactivators, leading to a strong increase of transcription of target genes. Interacts with the corepressor NCOR1. Interacts with SNW1. Interacts with IRX4, the interaction does not affect its transactivation activity. Interacts with CRY1 (By similarity). Interacts with CRY2 in a ligand-dependent manner (By similarity).

Family&Domains:

Composed of three domains: a modulating N-terminal domain, a DNA-binding domain and a C-terminal ligand-binding domain.

The 9aaTAD motif is a transactivation domain present in a large number of yeast and animal transcription factors.

Belongs to the nuclear hormone receptor family. NR1 subfamily.

Research Fields

· Human Diseases > Infectious diseases: Bacterial > Tuberculosis.

· Organismal Systems > Excretory system > Endocrine and other factor-regulated calcium reabsorption.

· Organismal Systems > Digestive system > Mineral absorption.

References

1). VDR activation attenuates osteoblastic ferroptosis and senescence by stimulating the Nrf2/GPX4 pathway in age-related osteoporosis. Free Radical Biology and Medicine, 2022 (PubMed: 36402439) [IF=7.4]
2). Novel Insights into the Cardioprotective Effects of Calcitriol in Myocardial Infarction. Cells, 2022 (PubMed: 35626713) [IF=6.0]
3). Eriodictyol ameliorates cognitive dysfunction in APP/PS1 mice by inhibiting ferroptosis via vitamin D receptor-mediated Nrf2 activation. Molecular Medicine, 2022 (PubMed: 35093024) [IF=5.7]

Application: WB    Species: Mouse    Sample: brain

Fig. 7 Eriodictyol up-regulates VDR expression and activates the Nrf2/HO-1 signaling pathway. A VDR expression in the mouse brain was detected using immunohistochemical staining. Then, B the VDR protein expression level in the mouse cortex and hippocampus was measured using Western blotting. C The VDR protein expression level in HT-22 cells was measured using Western blotting, and D its relative mRNA expression level was detected using q-PCR. E The levels of Nrf2, p-Nrf2 and HO-1 in the mouse cortex and hippocampus were measured using Western blotting. F The levels of Nrf2, p-Nrf2 and HO-1 in HT-22 cells were measured using Western blotting. G The level of Nrf2 in the nucleus and cytoplasm of HT-22 cells was detected using Western blotting, and Lamin B1 and β-actin were used as loading controls for the nuclear and cytoplasmic proteins, respectively. The data are presented as the means ± SD of three experiments. **P < 0.01 and ***P < 0.001 compared with the Aβ1–42 oligomer group. ##P < 0.01 compared with the control group
4). Monotropein inhibits colitis associated cancer through VDR/JAK1/STAT1 regulation of macrophage polarization. International Immunopharmacology, 2023 (PubMed: 37633235) [IF=5.6]

Application: WB    Species: Mouse    Sample:

FIGURE 2 PTS reduces reduction of NLRP3 inflammasome and apoptosis in DOX-treated mice. (A) WT C57/BL6J mice were pretreated with PTS (10 mg/kg) and afterwards with DOX (20 mg/kg cumulative dose) for 6 days. Immunochemistry staining of the liver sections with anti-NLRP3 (left, scale bar = 50 μm), the quantification of NLRP3 positive area in each group (right, n = 6); (B) qPCR analyses of NLRP3, IL-1β and IL-18 mRNA levels in each group (n = 6); (C) Western blot analyses of NLRP3, ASC, Caspase-1 p20, IL-1β, and IL-18 proteins and the quantification of the blots in each group (n = 4 per group); (D) Western blot analyses of Cleaved Caspase-3, BAX, and BCL-2 proteins (left) and quantification of the blots in each group (right, n = 4 per group).
5). Vitamin D stimulates miR-26b-5p to inhibit placental COX-2 expression in preeclampsia. Scientific Reports, 2021 (PubMed: 34045549) [IF=4.6]

Application: IHC    Species: human    Sample: placental

Figure 1.| Representative VDR, COX-2, and miR-26b-5p expression in placenta and trophoblasts from normotensive pregnant women and women complicated with preeclampsia (PE). (A) VDR expression and COX-2 expression in placental tissues from 12 pregnant women (6 from normotensive and 6 from PE). Strong VDR staining was seen in the placentas from normotensive pregnant women compared to those from women with PE. In contrast, intensive COX-2 expression was detected in placentas from PE specimens. Bar=100 micron.
6). Vitamin D stimulates placental L-type amino acid transporter 1 (LAT1) in preeclampsia. Scientific Reports, 2022 (PubMed: 35301401) [IF=4.6]

Application: IHC    Species: Human    Sample: trophoblast cells

Figure 1 Expression of LAT1 and VDR in normal and preeclamptic placentas. (A) Representative immunostaining images of LAT1 and VDR expressions in tissue sections from normal and preeclamptic (PE) placentas. Bar = 100 micron. (B) Representative blots of LAT1 and VDR expression in placenta from normotensive and PE pregnancies. (C,D) The bar graphs show the relative density of protein expression for LAT1 and VDR after normalization with β-actin expression in each sample. n = 5, #P < 0.05, PE vs Normal.

Application: WB    Species: Humna    Sample: trophoblast cells

Figure 2 Effects of 1,25(OH)2D3 and CoCl2 on LAT1 and VDR expression in placental trophoblasts. (A) Protein expression for LAT1 and VDR in HTR-8/SVneo trophoblast cells treated with different concentrations of CoCl2. The bar graphs show relative protein expression for LAT1 and VDR after normalized against β-actin in each sample from three independent experiments. CoCl2 induced a dose-dependent decrease in both LAT1 and VDR expression in trophoblasts. *P < 0.05, **P < 0.01, ***P < 0.001, CoCl2 treated vs control cells. (B) Protein expression for LAT1 and VDR in HTR-8/SVneo trophoblast cells treated with different concentrations of 1,25(OH)2D3. The bar graphs show relative protein expression for LAT1 and VDR after normalization with β-actin in each sample from four independent experiments. In contrast to CoCl2, 1,25(OH)2D3 stimulated LAT1 and VDR expression in a dose-dependent manner in trophoblast cells. #P < 0.05, ##P < 0.01, 1,25(OH)2D3 treated vs control cells.

Application: WB    Species: human    Sample: trophoblast cells

Figure 3.| Efects of 1,25(OH)2D3 on CoCl2-induced LAT1 expression in placental trophoblasts. (C) Protein expression of VDR and LAT1 expression in trophoblasts treated with VDR siRNA in the presence or absence of 1,25(OH)2D3. Inhibition of VDR expression attenuates 1,25(OH)2D3-stimulated LAT1 expression in trophoblast cells. Te bar graphs show relative VDR and LAT1 expression afer being normalized by β-actin in each sample from six independent experiments, *P<0.05, **P<0.01, treated vs control; ##P<0.01, ###P<0.001, 1,25(OH)2D3+VDR siRNA vs 1,25(OH)2D3 alone.
7). Wnt/PCP-YAP-BIRC2 axis maintains cartilage stem/progenitor cell homeostasis in osteoarthritis. Research Square, 2022

Application: WB    Species: Human    Sample: CSPCs

Figure 3. Wnt5A/B upregulates YAP in OA-CSPCs. a The mRNA expression of the genes associated with stem cell function in OA-CSPCs. b The protein levels of YAP, FAP, VDR, TERT, and MMP3 in OA-CSPCs. c Immunofluorescence staining of YAP (red) in OA-CSPCs. Nuclei were stained by 4,6-diamidina-2-phenylin (DAPI,blue), Bars=100 μm. d The protein levels of YAP in OA-CSPCs derived from OA patients.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.